Drug Profile

LX 2006

Alternative Names: AAVrh.10hFXN; LX-2006

Latest Information Update: 22 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Weill Cornell Medicine
Developer LEXEO Therapeutics
Class Cardiovascular therapies; Gene therapies
Mechanism of Action Frataxin expression stimulants; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Friedreich's ataxia
New Molecular Entity No

Highest Development Phases

Phase I/II Cardiomyopathies

Most Recent Events

12 May 2025 LEXEO Therapeutics plans to begin enrollment in a prospective natural history CLARITY-FA study in Q2 2025
12 May 2025 LEXEO Therapeutics plans to initiate registrational trial for Cardiomyopathies by early 2026
07 Apr 2025 Pharmacodynamics, efficacy and adverse events data from a phase-I/II trial in Cardiomyopathies released by LEXEO Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com